Enanta Pharmaceuticals, Inc
$12.20
-$0.32 (-2.56%)
$12.19Day Range$12.61
Key Statistics
Market Cap
$355.33M
Shares Outstanding
29.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 21, 2013
Round Lot
100
Locale
US
Trading Data
Day Open
$12.49
Day High
$12.61
Day Low
$12.19
Volume
428.2K
VWAP
$12.25
Prev Close
$12.52
Transactions
--
Acc. Volume
--
About Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
PHARMACEUTICAL PREPARATIONSSIC 2834120 employees4 KINGSBURY AVENUE, WATERTOWN, MA, 02472617 607 0800IPO Mar 21, 2013US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001177648
- Composite FIGI
- BBG001V9NSB4
- Share Class FIGI
- BBG001V9NSC3
- Ticker Root
- ENTA
- SIC Code
- 2834
About Enanta Pharmaceuticals, Inc (ENTA) Stock
Enanta Pharmaceuticals, Inc (ENTA) closed the 2026-09-18 session at $12.20, down 2.56% versus the previous close (-0.32). The stock opened at $12.49 and traded between $12.19 and $12.61 during that session. Session trading volume was 428K shares. The volume-weighted average price (VWAP) is $12.25.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Enanta Pharmaceuticals, Inc has a market capitalization of $355.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ENTA is listed on the XNAS exchange. The company employs approximately 120 people. Enanta Pharmaceuticals, Inc is headquartered in WATERTOWN, MA. The recorded listing date is 2013-03-21.
On this page you can find market ENTA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.